Gene Data From HGNC: https://www.genenames.org/download/statistics-and-files/
Symbol:
CD74
Name:
CD74 molecule
Location:
05q33.1
Locus Group:
protein-coding gene
Gene Type:
Protein Coding
Locus Type:
gene with protein product
Clinical Trials Data: https://classic.clinicaltrials.gov/api/gui/ref/download_all
Clinical Studies
| NCT Number | Status | Brief Title | View |
|---|---|---|---|
| NCT03424603 | Study of STRO-001 an Anti-CD74 Antibody Drug Conjugate in Patients With Advanced B-Cell Malignancies | View | |
| NCT03399487 | A Study of LDK378 in Patients With Non-small Cell Lung Cancer Harboring ROS1 Rearrangement | View | |
| NCT03918655 | MIF Involvement in AML | View | |
| NCT06383884 | Patritumab Deruxtecan in Patients With Solid Tumor Harboring an NRG1 Fusion | View | |
| NCT00603668 | Phase III Study of Different Doses and Dose Schedules of Milatuzumab hLL1 in CLL | View | |
| NCT00868478 | The Humanized Monoclonal Antibody Milatuzumab for Refractory Chronic Lymphocytic Leukemia CLL | View | |
| NCT02201446 | The Role of Circulating Soluble CD74 in Acute Lung Injury | View | |
| NCT02603315 | Vascularity Impact on the Treatment Outcome in Malignant Pleural MesotheliomaVITMPM | View | |
| NCT02761863 | Effect of Expression of CD74 and VEGF on Outcome of Treatment in Patients With Malignant Pleural Mesothelioma | View | |
| NCT06563804 | A Study to Evaluate S227928 as a Single Agent and in Combination With Venetoclax in Patients With RR AML MDSAML or CMML | View | |
| NCT00989586 | Veltuzumab and Milatuzumab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma | View | |
| NCT01964157 | An Open-label Multicenter Phase II Study of LDK378 in Patients With Non-small Cell Lung Cancer Harboring ROS1 Rearrangement | View | |
| NCT05611853 | Study of BN301 an Anti-CD74 Antibody Drug Conjugate in Patients With Advanced B-Cell Malignancies | View | |
| NCT00504972 | Phase I Trial of Anti-CD74 hLL1 Antibody Therapy in B Cell Malignancies | View |